Search Results

China Medical System Holdings Limited is pleased to announce that on 11 June 2024, the New Drug Application of the Group’s innovative drug methylthioninium chloride enteric-coated sustained-release tablets has been approved by the National Medical Products Administration of China.

On June 25, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the “Product”) in atopic dermatitis (“AD”) in China.

China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets (“Desidustat Tablets” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA).

While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days after it was reported that he was under investigation for alleged medical insurance fraud in the country.

A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an investigation into China exec, the Huntington’s pipeline builds momentum and layoffs continue with Sana Biotechnology and 23andMe.

Accuray Incorporated announced that the registration dossier for the Accuray Precision® Treatment Planning System has been approved by the Chinese National Medical Products Administration.

ANEW MEDICAL, INC. announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW’s Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases.

YolTech has partnered with KACTUS, a leading developer serving the biopharmaceutical industry, to advance the commercialization of YolTech’s proprietary DNA editor, YolCas12TM, in Greater China.

JW Therapeutics Co. Ltd, an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the preliminary clinical data on relmacabtagene autoleucel injection in adults with active systemic lupus erythematosus in China at the 2024 European Alliance of Associations for Rheumatology Congress.